Protagonist Therapeutics, Inc. Share Price
NASDAQ: PTGX | Mid CapProtagonist Therapeutics, Inc. Stock Performance
Open $146.62 | Prev. Close $149.62 | Circuit Range N/A |
Day Range $142.47 - $146.81 | Year Range $54.63 - $159.99 | Volume 30,618 |
Average Traded $144.43 |
Protagonist Therapeutics, Inc. Share Price Today
As of 31 August 2026, Protagonist Therapeutics, Inc.'s share price is $144.22. The stock opened at $146.62, compared to its previous close of $149.62. During today's trading session, Protagonist Therapeutics, Inc.'s share price traded between $142.47 and $146.81, with an average price of $144.64. Over the past 52 weeks, the stock has recorded a high of $159.99 and a low of $54.63. In terms of performance, Protagonist Therapeutics, Inc.'s share price has risen by 56.57% over the last six months and is up 144.73% on a year-on-year basis.
Protagonist Therapeutics, Inc. Share Price Chart
Protagonist Therapeutics, Inc. Stock Fundamentals & Key Indicators
Market Cap $9.17B | PE Ratio (TTM) -70.35 | Dividend Yield N/A |
EPS (TTM) $-2.05 | Revenue (TTM) $46.02M | Return On Equity (TTM) -21.17% |
Profit Margin -282.83% | Debt to Equity 0.07 | Quarterly Earnings Growth YoY -18.46% |
Protagonist Therapeutics, Inc. Quarterly Profit & Loss
All figures in USD
Protagonist Therapeutics, Inc. Annual Profit & Loss
All figures in USD
About Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
Protagonist Therapeutics, Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $135.91 | $149.56 | +9.32% |
Jul 2026 | $123.85 | $136.81 | +11.83% |
Jun 2026 | $97.85 | $122.34 | +22.92% |
May 2026 | $99.13 | $99.53 | +0.61% |
Apr 2026 | $106.41 | $98.93 | -6.26% |
Mar 2026 | $91.34 | $105.54 | +14.57% |
Feb 2026 | $81.56 | $92.11 | +12.61% |
Jan 2026 | $86.93 | $81.80 | -6.29% |
Dec 2025 | $89.25 | $87.30 | -2.90% |
Nov 2025 | $79.14 | $89.90 | +14.33% |
Oct 2025 | $65.98 | $78.63 | +18.37% |
Sep 2025 | $59.18 | $66.43 | +12.73% |
PTGX Share Price FAQs
What is Protagonist Therapeutics, Inc. share price today?
What is the 52 week high and 52 week low of Protagonist Therapeutics, Inc. stock?
What is PTGX's market capitalisation today?
What is PTGX's net income for the last quarter?
What is the 5 year returns of PTGX?
What is the high & low stock price of PTGX today?
Can I buy PTGX shares in India?